Skip to main content

Ethnic Disparity Seen When Diagnosing Bacterial Vaginosis Using AI

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 27, 2023.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Dec. 27, 2023 -- Machine learning (ML) model performance for diagnosing bacterial vaginosis (BV) varies among ethnic groups, according to a study published online Nov. 17 in npj Digital Medicine.

Cameron Celeste, from the University of Florida in Gainesville, and colleagues examined the ability of four ML algorithms to diagnose BV. Fairness in the prediction of asymptomatic BV using 16S rRNA sequencing data from Asian, Black, Hispanic, and White women was investigated.

The researchers observed variation in general purpose ML model performances based on ethnicity. Models performed least effectively for Hispanic and Asian women when evaluating the metric of a false-positive (FPR) or false-negative rate (FNR). In general, models had the highest and lowest performance for White and Asian women, respectively.

"Here, we show that several supervised learning models perform differently for ethnic groups by assessing commonly used metrics, such as balanced accuracy and average precision, as well as more clinically relevant metrics, such as FPR and FNR, in a cohort of women with asymptomatic BV," the authors write. "The results provide evidence that there is a discrepancy in model performance between ethnicities."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.